Scaling RNA therapeutics sustainably using the ECO Synthesis Manufacturing Platform

In this presentation, we will demonstrate the scalability of ECO Synthesis™ while illustrating the ability to transition from research to manufacturing scale and cGMP production, highlighting its potential to exceed the productivity of traditional SPOS. Answering the call for a more scalable and sustainable process, Codexis introduced the ECO Synthesis™ Manufacturing Platform—a fully water-based, enzymatic, high-yielding production approach for safe, quality, and efficacious siRNA.

Register Free: https://www.pharmtech.com/pt_w/outsourcing

Event Overview:

Rapidly growing therapeutic oligonucleotide demand for large indications require innovative manufacturing solutions. Answering the call for a more scalable and sustainable process, Codexis introduced the ECO Synthesis® Manufacturing Platform — a fully aqueous, enzymatic, high yielding production approach for safe, quality, and efficacious siRNA. In this presentation, we characterize a 10 g synthesis of siRNA using the ECO Synthesis platform. Through the ECO Innovation lab, Codexis can now deliver up to 100 grams of GLP grade RNA to support tox studies. We will showcase how ECO Synthesis® can transition from research to manufacturing scale and cGMP production while highlighting its potential to exceed productivity of traditional SPOS.

Key Learning Objectives:

• Understand the need for scalable and sustainable oligonucleotide manufacturing
• Explore the ECO Synthesis® Manufacturing Platform supports scalable, high-quality siRNA Manufacturing

Who Should Attend:

• CMC and process development professionals
• Pharma drug/innovators
• RNA manufacturing leaders

Speaker:

Derek Gauntlett
Vice President, Development.
Codexis

Derek Gauntlett joined Codexis in 2023 to lead process development for the ECO Synthesis® platform, bringing over 13 years of biotech R&D experience across therapeutic modalities from preclinical to commercialization. Previously, he drove RNA therapeutics development at LGC Axolabs and advanced process sciences at BioMarin. He holds a BS from California State Polytechnic University, Humboldt, and an MBA from Sonoma State.

Register Free: https://www.pharmtech.com/pt_w/RNAi_demand